Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

NEULAND LABORATORIES LTD.

NSE : NEULANDLABBSE : 524558ISIN CODE : INE794A01010Industry : Pharmaceuticals & DrugsHouse : Private

BSE13043.8083.8 (+0.65 %)

PREV CLOSE ( ) 12960.00

OPEN PRICE ( ) 13125.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 3203

TODAY'S LOW / HIGH ( )12863.85 13280.00

52 WK LOW / HIGH ( )10060 19748.4

NSE13056.0096 (+0.74 %)

PREV CLOSE( ) 12960.00

OPEN PRICE ( ) 12997.00

BID PRICE (QTY) 13056.00 (187)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 39031

TODAY'S LOW / HIGH( ) 12823.00 13296.00

52 WK LOW / HIGH ( )10190.7 19747

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 07-01 1984

Management Info

Davuluri Rama Mohan Rao - Chairman Davuluri Saharsh Rao - Managing Director

Registered Office

Address 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee Hills,
Hyderabad,
Telangana-500033

Phone 040-67611600 / 67611700

Email neuland@neulandlabs.com

Website www.neulandlabs.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

04Feb Neuland Laboratories informs about ana
Neuland Laboratories has informed that the Company’s management will be..

27Jan Neuland Laboratories informs about ana
Neuland Laboratories has informed that the company will announce its res..

19Dec Neuland Laboratories informs about new
Pursuant to Regulation 47 of the Securities and Exchange Board of India..

15Dec Neuland Laboratories informs about an
Neuland Laboratories has informed that the Company’s management will be..

08Dec Neuland Laboratories informs about re-
Pursuant to SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 date..

Financials

Rs. in Millions

	QTR Dec 25	ANNUAL 25
Net Profit	404.17	2594.26
Gross Profit	542.72	3453.74
Operating Profit	849.79	3428.08
Net Sales	4397.09	14768.37

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Kwality Pharma (BSE) 1431.20 (5.08%)	M.Cap ( in Cr)1485.04
Sanofi Cons. Health (BSE) 4299.65 (1.54%)	M.Cap ( in Cr)9902.36
Astrazeneca Pharma I (BSE) 8878.75 (0.59%)	M.Cap ( in Cr)22196.88
NGL Fine-Chem (BSE) 2291.65 (2.29%)	M.Cap ( in Cr)1415.79
Haleos Labs (BSE) 1355.75 (3.19%)	M.Cap ( in Cr)409.88

Shareholding Pattern

	PROMOTERS	32.63%
	NON-INSTITUTION	31.76%
	MUTUAL FUNDS/UTI	10.39%
	FI/BANKS/INSURANCE	1.18%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
LIC MF Healthcare F...	4.12
Bajaj Finserv Healt...	2.78
ITI Pharma & Health...	2.08
PGIM India Healthca...	1.82
HSBC Focused Fund-Reg(G)	1.74
Tata Nifty MidSmall...	1.74
Motilal Oswal Nifty...	1.73

Risk Disclosures on Derivatives

Smart Quotes

NEULAND LABORATORIES LTD.